Kymera Therapeutics Inc. logo

Kymera Therapeutics Inc.

KYMR | NASDAQ
Chart Builder DCF Calculator
$117.67
-$0.08 (-0.07%)
At close: Sep 21, 2026, 4:00 PM ET
$117.67
$0 (0.00%)
After-hours: Sep 21, 2026, 7:30 PM ET

Market Data

Market Cap
$9.69B
Enterprise Value
$9.07B
Beta
1.97
Average Volume
759.43K
Shares Outstanding (Diluted)
98.18M
Shares Change YoY
22.04%
Institutional Ownership
98.73%
Exchange
NASDAQ
ISIN
US5015751044

Price Performance

Price Change 1M
-1.7%
Price Change 3M
19.8%
Price Change 6M
49.1%
Price Change YTD
61.7%
Price Change 1Y
130.7%
Price Change 3Y
572.4%
Price Change 5Y
88.3%
1M CAGR (ann.)
10.7%
1Y CAGR (ann.)
144.7%
5Y CAGR (ann.)
12.1%
All-Time CAGR
23.1%

Valuation

PE Ratio
-36.21
Forward PE
N/A
PEG Ratio
-6.52
Forward PEG
-1.19
PS Ratio
92.19
Forward PS
240.80
PB Ratio
6.41
P/FCF Ratio
-40.68
P/Adj. FCF Ratio
-31.93
P/OCF Ratio
-48.83
EV/Sales
86.39
EV/EBIT
-30.27
EV/EBITDA
-30.98
EV/FCF
-38.12
Earnings Yield
-2.8%
FCF Yield
-2.5%
Adj. FCF Yield
-3.1%

Financial Health

Net Cash
$690.99M
Total Debt
$82.22M
Cash & Short-Term Investments
$690.99M
Total Assets
$1.65B
Current Ratio
9.83
Quick Ratio
9.91
Debt / Equity Ratio
0.05
Debt / EBITDA
-0.28
Debt / FCF
-0.35
OCF / Debt
-2.88
Interest Coverage
-1,659.61
Altman Z-Score
40.48
Piotroski F-Score
5

Margins & Profitability

Gross Profit Margin
102.0%
Operating Profit Margin
-333.5%
EBITDA Margin
-278.9%
Net Profit Margin
-285.4%
FCF Margin
-226.7%
Adj. FCF Margin
-288.8%
SBC / Revenue
62.1%
SBC Impact (per share)
-27.4%

Returns

Return on Assets
-18.2%
Return on Equity
-21.5%
Return on Invested Capital
-22.1%
Return on Capital Employed
-22.3%
Return on Tangible Assets
-18.2%

Historical Growth (CAGR)

Revenue CAGR 3Y
26.7%
Revenue CAGR 5Y
10.2%
Revenue CAGR 10Y
N/A
EPS CAGR 3Y
-13.6%
EPS CAGR 5Y
-6.5%
EPS CAGR 10Y
N/A
FCF CAGR 3Y
-23.9%
FCF CAGR 5Y
-12.9%
FCF CAGR 10Y
N/A

Analyst Forecasts

Analyst Rating
Buy
Analyst Count
27
EPS Growth Next 3Y
-25.4%
Revenue Growth Next 3Y
-14.3%
Earnings Date
Nov 2, 2026
EPS Estimate (next Q)
-$1.25
EPS Growth Est (next Q)
38.9%
Revenue Est (next Q)
$3.28M
Revenue Growth Est (next Q)
18.5%

Fair Value Estimates

Graham Number
N/A
Graham Upside
N/A
Lynch Fair Value
N/A
Lynch Upside
N/A
Price Target
$136.75
Price Target Upside
16.2%

Cash Flow

Operating Cash Flow
$-236.76M
Free Cash Flow
$-237.96M
Adj. Free Cash Flow
$-303.16M
FCF Per Share
-$2.42
OCF Per Share
-$2.41
OCF/S Ratio
-225.5%

Income Statement

Revenue
$104.99M
Gross Profit
$107.07M
Operating Income
$-350.18M
EBITDA
$-292.76M
Net Income
$-299.65M
EPS (Diluted)
-$3.25
Revenue / Employee
$384.58K
Profit / Employee
$-1.1M
Employees
273

© 2026 bestshares.com. All rights reserved.